Stoke Therapeutics Inc. (STOK)
STOK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/0001193125-26-108362-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | STOK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001623526 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $184.4M |
| Net income | -$6.9M |
| Operating income | -$20.6M |
| Net margin | -3.7% |
| Operating margin | -11.2% |
| Revenue growth | +404.5% |
| Cash | $84.2M |
| Total assets | $418.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $107.3M cash; operating cash flow -$52.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 65,406,268 (2026-10-30); 57,117,150 a year earlier; 44,653,782 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-03-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $11.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $11.3M | -$73.6M | -$62.7M | $107.3M | No debt tags | $28.2M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $9.3M | -$61.6M | -$56.6M | $110.0M | No debt tags | $27.6M | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $6.2M | -$50.0M | -$60.6M | $155.7M | No debt tags | $32.1M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $1.4M | -$57.9M | -$30.5M | $84.2M | No debt tags | $184.4M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $10.6M | -$38.3M | -$30.4M | $83.4M | No debt tags | $205.6M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $13.8M | -$23.5M | -$25.4M | $101.5M | No debt tags | $199.9M | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $158.6M | $112.9M | $131.8M | $274.8M | No debt tags | $190.9M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $22.6M | -$10.5M | -$23.2M | $128.0M | No debt tags | $36.6M | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-03 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-10-29 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 636 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | +18.6% |
| 3 months | -14.8% |
| Year to date | -15.9% |
| 1 year | +2.3% |
| From 52-week high | -30.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BRVE | Braveheart Bio Inc. | $19.49 | -0.66% | $1.8B |
| AGIO | Agios Pharmaceuticals Inc. | $30.15 | -4.56% | $1.8B |
| ZYME | Zymeworks Inc. | $26.45 | +0.80% | $1.8B |
| ETON | Eton Pharmaceuticals Inc. | $63.88 | -0.08% | $1.8B |
| KLRA | Kailera Therapeutics Inc. | $12.57 | -5.28% | $1.6B |
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $15.13 | -5.85% | $1.6B |
| RARE | Ultragenyx Pharmaceutical Inc. | $15.90 | -1.12% | $1.6B |
| ANIP | ANI Pharmaceuticals Inc. | $70.89 | -0.77% | $1.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier